Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.38, read 2026-11-01
Ethical does not pass the values gate
Price83.09 USD
Fair valueUnder review
Ethical score10.0/100
Our investment reviews on this name
2026-10-11Read Distribution108.99-23.8% to today ✓Markup gives way to Distribution
2026-10-02Read Markup108.99-23.8% to today Distribution gives way to Markup after an 11% slide in 6 weeks
2026-08-21Read Distribution122.27-32.0% to today ✓Markup gives way to Distribution after an 18% slide in 7 weeks
2026-07-02Read Markup149.32-44.4% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Akamai Technologies holds its Distribution at $83.09. The statistical read favours the sellers, held for 9 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 9 days
Price at the screen
$83.09
Valuation
33.59 trailing · 13.56 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.62
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
49.44%
Below 33%
Interest-bearing debt is 49.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
6.39%
Below 33%
Cash held in interest-bearing accounts and securities is 6.4% of assets, under the one-third limit.
Pass
Receivables
13.14%
Below 49%
Money owed to the company is 13.1% of assets, under the 49% limit.
Pass
Revenue purity
1.68%
Below 5%
Only 1.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Akamai Technologies's business is in a permissible area, but its interest-bearing debt is about 49% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AKAM's ethical verdict changes
Today AKAM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.15x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Web delivery giant trips on ethical debt test
Every time you stream video or load a secure checkout, Akamai moves the traffic. Yet we are staying away. The shares trade at a 46 percent discount to our fair value, but that gap does not outweigh the red flags.
Revenue is growing just 6 percent, margins sit at 10 percent and return on equity is only 9 percent. A narrow moat and forward multiple of 16.7 times do not scream cheap when growth is this modest. The decisive issue is the ethical screen, which fails on the debt ratio.
Analysts may still like the name and point to a 165 dollar median target, but we do not override a clear ethical fail. That screen exists for exactly these cases. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AKAM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Distribution$85.93-0.7%Entry 19
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Distribution$86.53-6.7%Entry 18
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Distribution$92.72+0.0%Entry 17
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Distribution$92.72+0.0%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Distribution$92.72+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Distribution$92.72-6.9%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Distribution$99.59+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Distribution$99.59+13.4%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 13.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$87.81+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157.
2026-10-18Distribution$87.81-19.4%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 19.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 59% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (22 analysts) rates it buy, with a mean price target of $157.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
